Australia markets closed

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.2500+0.0500 (+1.19%)
At close: 4:00PM EDT
4.0700 -0.18 (-4.24%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.2000
Open4.2239
Bid4.0400 x 1800
Ask4.0800 x 1100
Day's range4.1300 - 4.4300
52-week range3.7800 - 77.7700
Volume2,719,352
Avg. volume4,027,881
Market cap154.341M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)-3.9820
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.00
  • GlobeNewswire

    Modified long-term share-based incentive program for 2021

    Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the β€œLTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the

  • GlobeNewswire

    Orphazyme provides regulatory and financial updates

    Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC). The company also announces that it now expects to end 2021 with a cash position of no les

  • PR Newswire

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.